MAPT and Alzheimer disease: Thus, we postulate that CCH might lead to chronic neurodegeneration and cognitive impairment in AD and VaD through reduction of cerebral glucose metabolism and consequently down-regulation of O-GlcNAcylation and hyperphosphorylation of tau.